Biologic Lyophilization Patents: Leaders, Trends & White Space 2026
Biologic Lyophilization Formulation Development Patents
A long tail, not a monopoly. the ranked leader holds 201 records but the top 5 combined are just 7.5% of all 10,484 records in scope. Filings hit their peak so far in 2017 at 660 records. Using only complete years, 2021 to 2024 fell 41%, from 516 to 304 records. That is a genuine slowdown in formal filing activity, not an artefact of publication lag, though the 2025-2026 figures will rise somewhat as later applications publish.
- 1TAKEDA PHARMA CO LTD1.9%
- 2AMGEN INC1.9%
- 3GLAXOSMITHKLINE BIOLOGICALS SA1.4%
- 4ABRAXIS BIOSCIENCE LLC1.2%
- 5IMA LIFE NORTH AMERICA INC1.1%
See the full biologic lyophilization formulation development analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on biologic lyophilization patents
Who are the leading patent holders in biologic lyophilization formulation?
The ranked list returns 100 companies, with the top-ranked assignee holding 201 records, well ahead of the fifth-place filer at 113 and tenth place at 86. Despite that gap at the top, the top 5 combined account for only 7.5% of all 10,484 records in scope, so no single company controls the field. Effective competitive tracking needs to look beyond the top few names into the broader ranked list, which includes large biologic originators, contract formulation specialists and drying-equipment manufacturers.
Is patent filing in biologic lyophilization still growing?
No, not over the most recent complete comparison window. Filing peaked in 2017 at 660 records, and using only complete years, activity fell 41% from 516 records in 2021 to 304 in 2024. Figures for 2025 and 2026 will rise somewhat as publication catches up, since publication typically lags filing by around 18 months, but the underlying complete-year trend is a genuine decline rather than a lull.
What technology areas dominate biologic lyophilization patents?
Medicinal-preparation claims under A61K appear in 90.0% of the 10,484 records, making it by far the largest class. Therapeutic-activity claims (A61P) sit at 34.5% and microorganism/genetic-engineering claims (C12N) at 19.5%. Drying-process claims under F26B, the more equipment- and parameter-focused class, appear in only 8.1% of records, indicating that most patenting activity concerns formulation ingredients and conditions rather than the physical drying process itself.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Biologic Lyophilization Formulation Development covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.